ClinicalTrials.gg
Status unknownNCT01443689Updated Nov 28, 2012

Allogenic Stem Cell Therapy in Patients With Acute Burn

A Phase 1/2 interventional study of human umbilical cord mesenchymal stem cells and human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells in Burns, sponsored by Shenzhen Beike Bio-Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-11-28.

Sponsored by Shenzhen Beike Bio-Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Burns with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Burns · China.

Planned enrollment
19th of 20
20 · median 67
Started
2011
with 3 others
Phase 1/2
4 of 24
2 open now
Registered
2nd of 24
by date

Among the 24 studies in Burns with a site in China, this one is the 19th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2011, is one of 4 in phase 1/2, and was the 2nd registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

10 of the 24 studies in Burns with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Burns with a site in China, or all of them as a file.
02

Study summary

Burn trauma,especially extensive ones, remains a life-threatening local and general inflammatory condition destroying the skin and underlying tissues, and resulting in serious sequelae. Remarkable progress has been achieved during last 30 years,stem cell therapy plays an important role in this progress. Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy for burn. In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation will be evaluated in patients with acute burn.

Read the detailed description

To investigate the safety and efficacy of human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells transplantation in patients of Acute, Moderate-Severe, Full-thickness burn.

03

Conditions studied

  • Burns

Browse trials for

Keywords

  • Extensive Burn
  • Human Cord Blood Mononuclear Cells
  • Human Umbilical Cord Mesenchymal Stem Cells
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between age 18- 65 years, both gender.
  • Diagnosed with Acute, Moderate-Severe, full-thickness burn:

Burn occurring within the 72 hours prior to administration. TBSA 20-55%, third degree wounds surface area \< 19 % ;

  • Willing to sign the Form.

Exclusion criteria

Exclusion Criteria:

  • All other burns except thermal origin.
  • Chronically malnourished, poor medical condition or shock
  • Systemic inflammatory response syndrome (SIRS) or septicopyemia
  • Moderate-severe inhalation injury airways to lung
  • +
  • disease, e.g. lupus erythematosus, multiple sclerosis.
  • Severe pulmonary and hematological disease, or hypo-immunity.
  • Currently undertaking other treatment that may affect the safety/efficacy of stem cells.
  • Pregnancy or lactation
  • Enrollment in other trials in the last 3 months.
  • Other criteria the investigator consider improper for inclusion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Group1 :Conventional plus hUCMSCs treatment

    Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.

    Biological: human umbilical cord mesenchymal stem cells

  • Experimental
    Group 2: Conventional plus hCBMNCs and hUCMSCs therapy

    Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.

    Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells

  • Active comparator
    Group 3:Conventional therapy

    Participants will be given conventional therapy only with a 6 months follow-up.

    Drug: Conventional therapy

Interventions

  • Participants will be given conventional therapy plus hUCMSCs transplantation.

  • Biologicalhuman cord blood mononuclear cells and human umbilical cord mesenchymal stem cells

    Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.

  • DrugConventional therapy

    Participants will be given conventional therapy only.

06

What researchers measure

Primary outcomes

  1. The ratio of wound contraction and re-epithelialisation

    Time frame: 6 months after treatment

  2. Complete healing time for investigated burn area

    Time frame: 6 months after treatment

  3. Vancouver Scar Scale

    Time frame: 6 months after treatment

Secondary outcomes

  1. Incidence of infections and bleedings in burn wounds

    Time frame: 6 months after treatment]

  2. Engraftment assessment: Vitality of the graft

    Time frame: 6 months after treatment]

  3. McGill pain Questionnaire

    Time frame: 6 months after treatment

  4. Incidence of Adverse Events and Serious Adverse Events

    Time frame: 6 months after treatment

07

Study locations

1 of 1 sites recruiting
  • The Second Affiliated Hospital of Kunmming Medical College
    Kunming, Yunnan 650033, China
    Recruiting
    • Jinfeng Fu · Contactynfjf@hotmail.com · 86-871-5351281
    • Jinfeng Fu · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Mar 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2011
First posted
Sep 30, 2011
Start
Jul 2011
Primary completionEst.
Mar 2013
CompletionEst.
Jul 2013
Last update
Nov 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01443689
Lead sponsor
Shenzhen Beike Bio-Technology Co., Ltd.
Collaborators
The Second Affiliated Hospital of Kunming Medical University
Responsible party
Sponsor
First posted
Sep 30, 2011
Start date
Jul 2011
Primary completion
Mar 2013 (estimated)
Completion
Jul 2013 (estimated)
Last update
Nov 28, 2012

Study contacts

Jinfeng Fu
Contact
ynfjf@hotmail.com
86-871-5351281

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion